<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8199">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01863004</url>
  </required_header>
  <id_info>
    <org_study_id>DYSF001A1</org_study_id>
    <secondary_id>2011DR1148</secondary_id>
    <nct_id>NCT01863004</nct_id>
  </id_info>
  <brief_title>Proteasomal Inhibition for Patients With Mis-sense Mutated Dysferlin</brief_title>
  <acronym>Dysferlin</acronym>
  <official_title>Proteasomal Inhibition for Patients With Mis-sense Mutated Dysferlin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Sinnreich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dysferlin is a protein with an important role in the repair of muscle surface membranes.
      Mutations in dysferlin cause different forms of muscular dystrophies. Dysferlinopathies are
      inherited in an autosomal recessive manner, and many patients with this disease harbor
      mis-sense mutations in at least one of their two pathogenic DYSF alleles. These patients
      have significantly reduced or absent dysferlin levels in skeletal muscle, suggesting that
      dysferlin encoded by mis-sense alleles is rapidly degraded by the cell's quality-control
      system. In a series of in-vitro experiments we showed that mis-sense mutated dysferlin can
      be salvaged from degradation by proteasomal inhibition. This resulted in an increase of
      functional dysferlin protein and a subsequent repair of plasma membranes of cultured
      patient-derived muscle cells. In this proof-of-concept study we would like to test wether
      proteasomal inhibition can salvage mis-sense mutated dysferlin in patients harboring certain
      dysferlin mis-sense mutations.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Dysferlin protein expression levels change from baseline over 5 days assessed by repeated biopsies and blood draws in skeletal muscle and in blood monocytes following administration of a single dose of Bortezomib.</measure>
    <time_frame>repeated needle muscle biopsies over a five day period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Repeated needle muscle biopsies and blood draws will be performed after administration of a single dose of Bortezomib (Velcade) to assess dysferlin protein expression in skeletal muscle and in blood monocytes over a five day period.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Dysferlinopathy</condition>
  <arm_group>
    <arm_group_label>Bortezomib (Velcade®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This study tests whether salvage of mis-sense mutated dysferlin through proteasomal inhibition seen in cultured muscle cells can be translated into patients harboring dysferlin mis-sense mutations. The proteasomal inhibitor Bortezomib (Velcade®) is already approved as a medication for the treatment of multiple myeloma in Switzerland and in other countries.
Following an administration of a single dose of Bortezomib repeated needle muscle biopsies and blood draws will be performed to assess dysferlin levels in skeletal muscle and blood monocytes over a five day period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <arm_group_label>Bortezomib (Velcade®)</arm_group_label>
    <other_name>Velcade®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  must carry at least one allele of a salvageable mis-sense mutation of dysferlin

          -  Age ≥ 18 years

          -  Written informed consent

        Exclusion Criteria:

          -  Bleeding disorder

          -  Acute or chronic kidney failure (CCL &lt;50 ml/min)

          -  Advanced liver disease or active hepatitis

          -  Congestive heart failure NYHA III and IV

          -  Pregnancy or nursing

          -  Immunosuppression (prednisolone doses below 20 mg/d are allowed)

          -  Therapy with strong inhibitors of cytochrome P450 3A4

          -  HCV or HIV infection

          -  Regular alcohol consumption (&gt;14 drinks a week)

          -  Drug addiction
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Sinnreich, Prof. Dr. med. Dr. phil.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sponsor-Investigator, Neuromuscular Center, Neurology Clinic, University Hospital Basel, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Sinnreich, Prof. Dr. med. Dr. phil.</last_name>
    <phone>0041-61-55</phone>
    <phone_ext>86792</phone_ext>
    <email>michael.sinnreich@usb.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neuromuskuläres Zentrum, Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Sinnreich, Prof. Dr. med. Dr. phil.</last_name>
      <phone>0041-61-265 41 30</phone>
      <email>michael.sinnreich@ubs.ch</email>
    </contact>
    <investigator>
      <last_name>Michael Sinnreich, Prof. Dr. med. Dr. phil.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bilal A. Azakir, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Azakir BA, Di Fulvio S, Kinter J, Sinnreich M. Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells. J Biol Chem. 2012 Mar 23;287(13):10344-54. doi: 10.1074/jbc.M111.329078. Epub 2012 Feb 8.</citation>
    <PMID>22318734</PMID>
  </results_reference>
  <results_reference>
    <citation>Di Fulvio S, Azakir BA, Therrien C, Sinnreich M. Dysferlin interacts with histone deacetylase 6 and increases alpha-tubulin acetylation. PLoS One. 2011;6(12):e28563. doi: 10.1371/journal.pone.0028563. Epub 2011 Dec 8.</citation>
    <PMID>22174839</PMID>
  </results_reference>
  <results_reference>
    <citation>Azakir BA, Di Fulvio S, Salomon S, Brockhoff M, Therrien C, Sinnreich M. Modular dispensability of dysferlin C2 domains reveals rational design for mini-dysferlin molecules. J Biol Chem. 2012 Aug 10;287(33):27629-36. doi: 10.1074/jbc.M112.391722. Epub 2012 Jun 26.</citation>
    <PMID>22736764</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 22, 2013</lastchanged_date>
  <firstreceived_date>April 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Basel, Switzerland</investigator_affiliation>
    <investigator_full_name>Michael Sinnreich</investigator_full_name>
    <investigator_title>Prof. Dr. med. Dr. phil., Head Neuromuscular Center, Department of Neurology</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophies, Limb-Girdle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
